

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute PTO/SB/8A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO (Modified)				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/043,649
				Filing Date	January 10, 2002
				First Named Inventor	MANCEBO, Helen
				Group Art Unit	1645-1644
				Examiner Name	M. DiBona
Sheet	1	of	2	Attorney Docket Number	A-70219-1/RMS/DHR (467802-52)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1				
	A2				
	A3				
	A4				
	A5				
	A6				

RECEIVED
JAN 31 2003
TECH CENTER 1800/2800

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ² Number ³ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
MD	B1	WO 95/26983 A2	10-12-1995	MAX-PLANCK-GESELLSCHAFT	PP 7-8, 15, claims 1-4	
MD	B2	WO 00/58473 A2	10-05-2000	CURAGEN CORPORATION	pp 4690-4692	
MD	B3	WO 02/16599 A2	02-28-2002	CURAGEN CORPORATION	pp 97-104, claims 1-49	
MD	B4	WO 02/42452 A2	05-30-2002	HOSPITAL FOR SICK CHILDREN	claims 1-39, ex. 1-2, table 4	
MD	B5	WO 02/42457 A1	05-30-2002	BRISTOL-MYERS SQUIBB	claims 1-20, fig. 1-2, ex. 1-7	


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ⁶
MD	C1	PANDEY A et al., "Characterization of a Novel Src-Like Adapter Protein that Associates with the Eck Receptor Tyrosine Kinase," J. Biol. Chem. 270(33):19201-19204 (Aug. 1995)				
MD	C2	Database EMBL Online, Acc. No. Q60898, Nov. 1, 1996. Src-like adapter protein, one page				
MD	C3	TANG, J et al., "SLAP, a dimeric adapter protein, plays a functional role in T cell receptor signaling," Proc. Nat. Acad. Sci. USA 96:9775-9780 (1999)				
MD	C4	Database EMBL Online, Acc. No. AK025645, Sep. 29, 2000. Homo sapiens cDNA: FLJ21992 fis, clone HEP06554, one page				
MD	C5	Database EMBL Online, Acc. No. AL050318, May 26, 1999. Human DNA sequence from clone RP5-977B1 on chromosome 20 Contains ESTs, STSS, GSSs and three putative CpG islands. 48 pages				
MD	C6	Database EMBL Online, Acc. No. AI430952, Mar. 16, 1999. mj43c04.x1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone IMAGE:478854 3' similar to TR:Q13239 Q13239 PUTATIVE SRC-LIKE ADAPTER PROTEIN; mRNA sequence. 2 pages				
MD	C7	Database EMBL Online, Acc. No. AA959151, May 11, 1998. vz51g06.r1 Soares 2NbMT Mus musculus cDNA clone IMAGE:1330042 5' similar to TR:Q13239 Q13239 PUTATIVE SRC-LIKE ADAPTER PROTEIN, mRNA sequence. 2 pages				
MD	C8	Database EMBL Online, Acc. No. AI510095, Mar. 17, 1999. mj43c04.y1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone IMAGE:478854 5' similar to TR:Q13239 Q13239 PUTATIVE SRC-LIKE ADAPTER PROTEIN; mRNA sequence. 2 pages				

Examiner Signature	<i>Maname DiBona</i>	Date Considered	11/17/04
--------------------	----------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1101652_1.DOC



Substitute PTO/SB/BA (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/043,649
				Filing Date	January 10, 2002
				First Named Inventor	MANCEBO, Helen
				Group Art Unit	1645 1644
				Examiner Name	M. DiBenedetto
Sheet	2	of	2	Attorney Docket Number	A-70219-1/RMS/DHR (467802-52)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
MD	C9	Holland SJ, et al., "Functional cloning of Src-like adapter protein-2 (SLAP-2), a novel inhibitor of antigen receptor signaling." J Exp Med. 2001 Nov 5;194(9):1263-76.		
MD	C10	Sosinowski T, et al., "Src-like adaptor protein (SLAP) is a negative regulator of T cell receptor signaling." J Exp Med. 2000 Feb 7;191(3):463-74.		
MD	C11	Database EMBL Online, Acc. No. AF290985. Dec. 9, 2001. Homo sapiens Src-like adaptor protein-2 mRNA, complete cds.		
MD	C12	Database Genbank online, Acc. No. AF326353. Nov. 8, 2001. Homo Sapiens Src-like adapter protein-2 mRNA, complete cds. one page		
MD	C13	Database Genbank online, Acc. No. NM_006748. Nov. 5, 2002. Homo sapiens Src-like-adaptor (SLA), mRNA. one page		
MD	C14	Rudd CE, and Schneider H. "Lymphocyte signaling: Cbl sets the threshold for autoimmunity." Curr Biol. 2000 May 4;10(9):R344-7.		
MD	C15	Ota S, et al., "The RING finger domain of Cbl is essential for negative regulation of the Syk tyrosine kinase." J Biol Chem. 2000 Jan 7;275(1):414-22.		
MD	C16	Rao N, et al., "The linker phosphorylation site Tyr292 mediates the negative regulatory effect of Cbl on ZAP-70 in T cells." J Immunol. 2000 May 1;164(9):4616-26.		

RECEIVED
JAN 31 2003
TECH CENTER 1600/2800

Examiner Signature	Marianne DiBenedetto	Date Considered	11/17/04
--------------------	----------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1101652_1.DOC